Marina Biotech Inc. (OTCQB: MRNA) filed a 10K with the SEC on April 5, 2017, for its year ended December 31, 2016. The late stage biopharmaceutical company summarized its achievements in 2016 and provided an outlook into its 2017 performance, including its planned clinical trials in 2018. Marina Biotech specializes in creating and commercializing innovative therapies for treatments of cancer, hypertension, and arthritis.
The firm plans to move by the first quarter of 2018 into a phase 3 clinical study of its drug candidate, IT-102, a fixed dose combination (FDC) bi-layer tablet, said Joseph Ramelli, chief executive officer of Marina Biotech. It recently signed an agreement for Windlas Healthcare Limited to manufacture the tablet, positioning Marina Biotech for the Phase 3 study. That India-based firm has facilities that are approved by the Food & Drug Administration (FDA) in the U.S., as well as…
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer